Patents-Review.com
ClassID:

20901 ⎘

A61K38/085 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof; Peptides having 5 to 11 amino acids Angiotensins

Recent Application in this class:
#1
20260060960
2026-03-05

GAMMA-SECRETASE INHIBITORS FOR USE IN THE TREATMENT OF INHERITED EPIDERMOLYSIS BULLOSA

 #2
20250332213
2025-10-30

EXTENDED-RELEASE INJECTABLE GEL FORMULATIONS CONTAINING ANGIOTENSIN-(1-7) OLIGOPEPTIDES OR VARIANTS THEREOF

 #3
20250281566
2025-09-11

EXTENDED-RELEASE INJECTABLE GEL FORMULATIONS CONTAINING ANGIOTENSIN-(1-7) OLIGOPEPTIDES OR VARIANTS THEREOF

 #4
20250206779
2025-06-26

ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

 #5
20250177476
2025-06-05

ANG-(1-7) OLIGOPEPTIDE DERIVATIVES FOR USE IN MITIGATING AMYLOID-RELATED IMAGING ABNORMALITIES

 #6
20250090622
2025-03-20

ANGIOTENSIN COMPOSITIONS AND METHODS RELATED THERETO

 #7
20250082716
2025-03-13

REPRESSED ANG 1-7 IN COVID-19 IS INVERSELY ASSOCIATED WITH INFLAMMATION AND COAGULATION

 #8
20250034209
2025-01-30

ANG (1-7) DERIVATIVE OLIGOPEPTIDES AND METHODS FOR USING AND PRODUCING THE SAME

 #9
20250000932
2025-01-02

DIAGNOSIS AND TREATMENT OF VASODILATORY SHOCK

 #10
20240285569
2024-08-29

METHODS FOR DECREASING INJURIES ASSOCIATED WITH INTRAOPERATIVE HYPOTENSION

 #11
20240197812
2024-06-20

Methods of Treating Cardiac Injury

 #12
20240189383
2024-06-13

Application of Inhibitors Targeting CD226 Molecules in Anti-Tumor Metastasis

 #13
20240123023
2024-04-18

PHARMACEUTICAL ANGIOTENSIN-(1-7) COMPOSITIONS IN THE TREATMENT OF (SARS)-COV- OR (SARS)-COV-2-INFECTION RELATED DISEASES

 #14
20240025904
2024-01-25

PDE9 INHIBITORS FOR TREATING CARDIAC FAILURE

 #15
20230338348
2023-10-26

RENIN-ANGIOTENSIN SYSTEM (RAS) MODULATORS FOR TREATMENT OF VIRAL INFECTIONS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS OF TREATING USING THE SAME

 #16
20230233713
2023-07-27

A HYPERTENSION ANIMAL MODEL AND METHODS OF USE

 #17
20230226141
2023-07-20

ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSION

 #18
20230226140
2023-07-20

ANG (1-7) DERVIATIVE OLIGOPEPTIDES FOR THE TREATMENT OF PAIN

 #19
20230110554
2023-04-13

METHODS AND COMPOSITIONS FOR TREATMENT OF CORONAVIRUS INFECTION

 #20
20230104480
2023-04-06

MICELLES AND VESICLES FOR THE DELIVERY OF GLYCOPEPTIDES

 #21
20230041686
2023-02-09

Method for Producing Peptide Ace Inhibitors

 #22
20230000943
2023-01-05

METHOD OF INDUCING SYNAPTOGENESIS BY ADMINISTERING ANGIOTENSIN AND ANALOGUES THEREOF

 #23
20220331395
2022-10-20

EXTENDED-RELEASE INJECTABLE GEL FORMULATIONS CONTAINING ANGIOTENSIN-(1-7) OLIGOPEPTIDES OR VARIANTS THEREOF

 #24
20220288164
2022-09-15

METHOD TO INCREASE SYSTEMIC BLOOD PRESSURE IN SHOCK

 #25
20220280440
2022-09-08

METHOD FOR THE MANUFACTURE OF A DOSAGE FORM WITH MUCOADHESIVE PROPERTIES FOR BUCCAL ADMINISTRATION OF BIOLOGICS

 #26
20220273757
2022-09-01

METHODS FOR ADMINISTERING ANGIOTENSIN II BY MONITORING RENIN LEVELS

 #27
20220211798
2022-07-07

THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF

 #28
20220193183
2022-06-23

COMPOSITIONS AND METHODS FOR TREATING RENAL FAILURE

 #29
20220160816
2022-05-26

ANGIOTENSIN COMPOSITIONS AND METHODS RELATED THERETO

 #30
20220047669
2022-02-17

Angiotensin II alone or in combination for the treatment of hypotension

 #31
20210401788
2021-12-30

Methods for decreasing injuries associated with intraoperative hypotension

 #32
20210395308
2021-12-23

Ang (1-7) derivative oligopeptides and methods for using and producing the same

 #33
20210346461
2021-11-11

UTILIZATION OF ENDOGENOUS OUBAIN-REGULATING COMPOUNDS AND COMPOSITIONS THEREOF IN TREATMENT OF VASCULAR DISEASE

 #34
20210346460
2021-11-11

TREATMENTS FOR COVID-19-RELATED SYSTEMIC SCLEROSIS, VASCULAR INSUFFICIENCY, DISTAL ISCHEMIA, AND RELATED DISEASE CONDITIONS

 #35
20210213136
2021-07-15

Targeting PAX2 for the treatment of breast cancer

 #36
20210187058
2021-06-24

Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II

 #37
20210145922
2021-05-20

ANG (1-7) DERVIATIVE OLIGOPEPTIDES FOR THE TREATMENT OF PAIN

 #38
20210077567
2021-03-18

Targeted Angiotensin 1-7 Peptide Conjugates and Formation and Use Thereof

 #39
20210030834
2021-02-04

METHODS FOR ADMINISTERING ANGIOTENSIN II

 #40
20200376073
2020-12-03

METHOD OF TREATING LOW BLOOD PRESSURE

 #41
20200289667
2020-09-17

Targeting Macrophages to Modulate Electrical Conduction in the Heart

 #42
20200262870
2020-08-20

Ang (1-7) derivative oligopeptides and methods for using and producing the same

 #43
20200237853
2020-07-30

METHODS FOR TREATING HYPOTENSION

 #44
20200222494
2020-07-16

Angiotensin receptor agonists and uses thereof

 #45
20200222493
2020-07-16

Methods for administering angiotensin II

 #46
20200206302
2020-07-02

USE OF DES-ASPARTATE-ANGIOTENSIN I TO TREAT PATIENTS EXHIBITING INFLAMMATORY DISEASES AND THEIR SYMPTOMS

 #47
20200188473
2020-06-18

COMBINATION THERAPY FOR CANCER

 #48
20200164021
2020-05-28

METHODS FOR ENHANCING SYNAPTOGENESIS AND NEURITOGENESIS

 #49
20200085967
2020-03-19

TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER

 #50
20200046668
2020-02-13

Methods for decreasing injuries associated with intraoperative hypotension

 #51
20200009212
2020-01-09

Cyclodextrin-Nle3-A(1-7) compositions and their use

 #52
20190388496
2019-12-26

Ang (1-7) derivative oligopeptides for the treatment of pain

 #53
20190374597
2019-12-12

Method of treating low blood pressure

 #54
20190351009
2019-11-21

ANG (1-7) DERVIATIVE OLIGOPEPTIDES FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS

 #55
20190328828
2019-10-31

PHARMACEUTICAL COMPOSITION, PROCESS FOR PRODUCING THE SAME, USE OF A PEPTIDE, USE OF A PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DISEASES ASSOCIATED WITH INTRAOCULAR HYPERTENSION OR GLAUCOMA

 #56
20190328827
2019-10-31

Angiotensin II alone or in combination for the treatment of hypotension

 #57
20190262436
2019-08-29

Method for producing peptide ACE inhibitors

 #58
20190241616
2019-08-08

Angiotensin (1-7) analogs and methods relating thereto

 #59
20190183962
2019-06-20

ANGIOTENSIN COMPOSITIONS AND METHODS RELATED THERETO

 #60
20190134145
2019-05-09

METHOD FOR TREATING COGNITIVE DYSFUNCTION

 #61
20190117726
2019-04-25

Methods of treating cardiomyopathy associated with genetic disorders

 #62
20190070250
2019-03-07

Angiotensin II alone or in combination for the treatment of hypotension

 #63
20190000809
2019-01-03

ANGIOTENSIN IN TREATING BRAIN CONDITIONS

 #64
20180344800
2018-12-06

Method of treating low blood pressure

 #65
20180344799
2018-12-06

Methods and compositions for the treatment of epidermolysis bullosa

 #66
20180311306
2018-11-01

METHODS FOR TREATING HYPOTENSION

 #67
20180221433
2018-08-09

ANGIOTENSINS IN MUSCULAR DYSTROPHY

 #68
20180200327
2018-07-19

Method of treating low blood pressure

 #69
20180200326
2018-07-19

ANG-(1-7) AND DERIVATIVE OLIGOPEPTIDES FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY AND OTHER COGNITIVE IMPAIRMENTS

 #70
20180193407
2018-07-12

Angiotensin II alone or in combination for the treatment of hypotension

 #71
20180133282
2018-05-17

Method of treating low blood pressure

 #72
20180117115
2018-05-03

Methods for enhancing synaptogenesis and neuritogenesis

 #73
20180057537
2018-03-01

Ang (1-7) derivative oligopeptides and methods for using and producing the same

 #74
20180050079
2018-02-22

ANGIOTENSIN PEPTIDES IN TREATING MARFAN SYNDROME AND RELATED DISORDERS

 #75
20180028596
2018-02-01

ANG-(1-7) Derivative Oligopeptides for the Treatment of Pain and Other Indications

 #76
20170348392
2017-12-07

SOLVENT/POLYMER SOLUTIONS AS SUSPENSION VEHICLES

 #77
20170304391
2017-10-26

Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications

 #78
20170274038
2017-09-28

Use of des-aspartate-angiotensin I to treat patients exhibiting malignant growth, invasive growth, tumor, tumor metastasis or cancer

 #79
20170258766
2017-09-14

ANGIOTENSIN IN TREATING BRAIN CONDITIONS

 #80
20170224761
2017-08-10

Methods for administering angiotensin II

 #81
20170196931
2017-07-13

Methods of Administering Vasopressors

 #82
20170095526
2017-04-06

Method of treating low blood pressure

 #83
20170014471
2017-01-19

COMPOSITIONS AND METHODS FOR TREATING RENAL FAILURE

 #84
20160296591
2016-10-13

COMPOSITIONS AND METHODS FOR TREATMENT OF BDNF-RELATED CONDITIONS

 #85
20160271205
2016-09-22

Use of angiotensin II (AII) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps

 #86
20160206681
2016-07-21

Method for treating cognitive dysfunction

 #87
20160199436
2016-07-14

METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

 #88
20160129072
2016-05-12

Angiotensin II alone or in combination for the treatment of hypotension

 #89
20160074466
2016-03-17

ANGIOTENSINS FOR TREATMENT OF FIBROSIS

 #90
20160074465
2016-03-17

Methods for Treating Hypotension

 #91
20160074464
2016-03-17

ANGIOTENSINS IN MUSCULAR DYSTROPHY

 #92
20160051622
2016-02-25

Accelerated healing of eye injuries by angiotensin peptides

 #93
20160051621
2016-02-25

USE OF AN ANG-(1-7) RECEPTOR AGONIST IN ACUTE LUNG INJURY

 #94
20160038560
2016-02-11

ANGIOTENSIN PEPTIDES IN TREATING MARFAN SYNDROME AND RELATED DISORDERS

 #95
20150374822
2015-12-31

METHODS AND APPARATUS FOR THE ENHANCED DELIVERY OF THE PHYSIOLOGIC AGENTS TO TISSUE SURFACES

 #96
20150290291
2015-10-15

Solvent/polymer solutions as suspension vehicles

 #97
20150246093
2015-09-03

ORAL FORMULATIONS OF ANGIOTENSIN

 #98
20150238560
2015-08-27

Methods and compositions for the delayed treatment of stroke

 #99
20150190472
2015-07-09

Use of the angiotensin-(1-9) peptide or derivatives thereof, use of vectors overexpressing the ACE2 enzyme that produces angiotensin-(1-9) for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation

 #100
20150164980
2015-06-18

Angiotensin II alone or in combination for the treatment of hypotension

 #101
20150164979
2015-06-18

Use of des-aspartate-angiotensin I in inflammation-related pathologies and diseases

 #102
20150150936
2015-06-04

USE OF DES-ASPARTATE-ANGIOTENSIN I TO TREAT PATIENTS EXHIBITING HIGH BLOOD GLUCOSE LEVELS OR GLUCOSE-INDUCED PANCREATIC BETA CELL DEATH

 #103
20150147283
2015-05-28

Methods for limiting development of a skin wound

 #104
20150057216
2015-02-26

ANGIOTENSINS FOR TREATMENT OF FIBROSIS

 #105
20150031634
2015-01-29

Angiotensin peptides in treating marfan syndrome and related disorders

 #106
20140335074
2014-11-13

METHODS FOR IMPROVING MEDICAL THERAPIES

 #107
20140329747
2014-11-06

Compositions and methods for treating renal failure

 #108
20140315808
2014-10-23

INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM FOR THE TREATMENT OF RENAL, VASCULAR AND CARTILAGE PATHOLOGY

 #109
20140296143
2014-10-02

Angiotensin-(1-7) As A Chemoprevention Agent

 #110
20140094497
2014-04-03

Angiotensin in treating brain conditions

 #111
20140031286
2014-01-30

Angiotensin (1-7) Dosage Forms and Uses Thereof

 #112
20130274191
2013-10-17

Compositions comprising β-arrestin 1 and methods of use thereof for therapeutic modulation of aldosterone levels in heart disease

 #113
20130237478
2013-09-12

COMPOSITIONS AND METHODS FOR TREATMENT OF PERIPHERAL VASCULAR DISEASE

 #114
20130183367
2013-07-18

Peptides Des-[Asp]-[Ala], angiotensin-(1-7) agonist and pharmaceutical compositions for the treatment of diseases

 #115
20130123190
2013-05-16

Methods for treating combined radiation and thermal injury

 #116
20130095082
2013-04-18

Use of des-aspartate-angiotensin I in inflammation-related pathologies and diseases

 #117
20130035670
2013-02-07

Solvent/polymer solutions as suspension vehicles

 #118
20130034210
2013-02-07

Solvent/polymer solutions as suspension vehicles

 #119
20130023475
2013-01-24

C-Met receptor regulation by angiotensin IV (AT4) receptor ligands

 #120
20120329729
2012-12-27

Methods for treating diabetic foot ulcers

 #121
20120321701
2012-12-20

Ang-(1-7) receptor agonist

 #122
20120259318
2012-10-11

Solvent/polymer solutions as suspension vehicles

 #123
20120172301
2012-07-05

Pharmaceutical compositions comprising angiotensin-(1-9), derivatives thereof, or a vector expressing ACE2, useful for treating cardiovascular, pulmonary, cerebral, and/or renal remodeling

 #124
20120071397
2012-03-22

Methods for Hematopoietic Stem Cell Transplantation

 #125
20110318338
2011-12-29

Targeting PAX2 for the treatment of breast cancer

 #126
20110281805
2011-11-17

USE OF AN ANG-(1-7) RECEPTOR AGONIST IN ACUTE LUNG INJURY

 #127
20110264077
2011-10-27

Solvent/polymer solutions as suspension vehicles

 #128
20110256097
2011-10-20

Treatment of Conditions that Increase in Severity and/or Occurrence During One or More Phases of the Menstrual Cycle

 #129
20110243937
2011-10-06

TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER

 #130
20110229468
2011-09-22

TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER

 #131
20110229467
2011-09-22

TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER

 #132
20110223162
2011-09-15

Targeting PAX2 for the treatment of breast cancer

 #133
20110223161
2011-09-15

Targeting PAX2 for the treatment of breast cancer

 #134
20110217299
2011-09-08

Targeting PAX2 for the treatment of breast cancer

 #135
20110212089
2011-09-01

TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER

 #136
20110206666
2011-08-25

TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER

 #137
20110206665
2011-08-25

TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER

 #138
20110144026
2011-06-16

Method of treating low blood pressure

 #139
20110104111
2011-05-05

Osmotic drug delivery devices containing suspension formulations comprising particles having active agents and nonaqueous single-phase vehicles

 #140
20110091541
2011-04-21

Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications

 #141
20110021422
2011-01-27

Method and compositions for prevention and treatment of diabetic and aged skin

 #142
20100297209
2010-11-25

SOLVENT/POLYMER SOLUTIONS AS SUSPENSION VEHICLES

 #143
20100210565
2010-08-19

METHODS AND APPARATUS FOR THE ENHANCED DELIVERY OF PHYSIOLOGIC AGENTS TO TISSUE SURFACES

 #144
20100210533
2010-08-19

USE OF UROCORTIN AND CORTICOTROPIN-RELEASING FACTOR AS THERAPEUTIC AGENTS

 #145
20100209421
2010-08-19

Targeting PAX2 for the treatment of breast cancer

 #146
20100204154
2010-08-12

Use of the peptide RFMWMR as a therapeutic agent

 #147
20100204131
2010-08-12

USE OF A PEPTIDE AS A THERAPEUTIC AGENT

 #148
20100197604
2010-08-05

USE OF PEPTIDE AS A THERAPEUTIC AGENT

 #149
20100196452
2010-08-05

Pharmaceutical compositions and methods for treating erectile dysfunction

 #150
20100158995
2010-06-24

SYSTEMS FOR DELIVERY AND RELEASE OF ANGIOTENSIN-(1-7)

 #151
20100144624
2010-06-10

Process for the preparation of compositions of AT1 receptor antagonist and Angiotensin—(1-7)

 #152
20100143317
2010-06-10

Infarct area perfusion-improving compositions and methods of vascular injury repair

 #153
20100119482
2010-05-13

Treatment of Conditions Through Modulation of the Autonomic Nervous System During at Least One Predetermined Menstrual Cycle Phase

 #154
20090304818
2009-12-10

METHOD OF TREATMENT

 #155
20090227507
2009-09-10

Angiotensin (1-7) Dosage Forms and Uses Thereof

 #156
20090221498
2009-09-03

Method for modulating, treating and/or preventing metabolic syndrome using MAS-G-protein-coupled receptor agonists

 #157
20090220507
2009-09-03

INHIBITION OF EXTRACELLULAR SIGNAL-REGULATED KINASE 1/2 AS A TREATMENT FOR CARDIAC HYPERTROPHY AND HEART FAILURE

 #158
20090192119
2009-07-30

Inhibition of the renin-angiotensin system for the treatment of renal, vascular and cartilage pathology

 #159
20090069246
2009-03-12

Methods of promoting hematopoietic and mesenchymal cell proliferation and differentiation

 #160
20090062210
2009-03-05

Methods for promoting erythropoiesis

 #161
20090012005
2009-01-08

Use of an angiotensin IV antagonist to treat insulin resistance or cardiovascular risk related to metabolic syndrome

 #162
20080312129
2008-12-18

Use of Mas G-Protein-Coupled Receptor Agonists and Antagonists, as Apoptotic-Activity Modulators for Study, Prevention and Treatment of Diseases

 #163
20080293634
2008-11-27

C-Met receptor regulation by angiotensin IV (AT) receptor ligands

 #164
20080249015
2008-10-09

Use of des-aspartate-angiotensin I

 #165
20080221036
2008-09-11

Use of AGT and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions

 #166
20080194485
2008-08-14

Detection and Use of Prolylcarboxypeptidase

 #167
20080167252
2008-07-10

Method for treating a patient undergoing chemotherapy

 #168
20080167251
2008-07-10

Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth

 #169
20080131406
2008-06-05

Angiotensin I Derivatives

 #170
20080108575
2008-05-08

Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications

 #171
20080039363
2008-02-14

Radiation therapy methods

 #172
20080008701
2008-01-10

C-Met receptor regulation by angiotensin IV (AT) receptor ligands

 #173
20070134155
2007-06-14

Pharmaceutical compounds

 #174
20070111929
2007-05-17

Methods for the treatment of anxiety and for identification of anxiolytic agents

 #175
20060193918
2006-08-31

Solvent/polymer solutions as suspension vehicles

 #176
20060076011
2006-04-13

Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces

 #177
20060057119
2006-03-16

Biologic skin repair and enhancement

 #178
20060029678
2006-02-09

Process for the production of implants

 #179
20050277595
2005-12-15

Methods for treating a patient undergoing chemotherapy

 #180
20050256028
2005-11-17

Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase

 #181
20050142130
2005-06-30

Use of angiotensin-(1-7) for preventing and/or reducing the formation of neointima

 #182
20050119323
2005-06-02

Anticancer agents

 #183
20050119180
2005-06-02

Use of angiotensin 1-7 for enhancing cardiac function

 #184
20050069533
2005-03-31

Systems for delivery and release of angiotensin-(1-7)

 #185
20050032688
2005-02-10

Use of angiotensin II fragments and analogs thereof in tissue repair